Published in Support Care Cancer on August 22, 2013
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol (2014) 1.71
Patients' preferences for bone metastases treatments in France, Germany and the United Kingdom. Support Care Cancer (2014) 0.88
Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Support Care Cancer (2015) 0.85
Emerging Therapeutic for the Treatment of Skeletal-related Events Associated With Metastatic Castrate-resistant Prostate Cancer. Rev Urol (2014) 0.81
Targeting bone metabolism in patients with advanced prostate cancer: current options and controversies. Int J Endocrinol (2015) 0.80
Chemotherapy- and irradiation-induced bone loss in adults with solid tumors. Curr Osteoporos Rep (2015) 0.79
Prostate cancer and bone: the elective affinities. Biomed Res Int (2014) 0.78
Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. Support Care Cancer (2014) 0.78
Validation of International Classification of Diseases coding for bone metastases in electronic health records using technology-enabled abstraction. Clin Epidemiol (2015) 0.77
Contribution of acidic extracellular microenvironment of cancer-colonized bone to bone pain. Biochim Biophys Acta (2015) 0.77
Patient-reported outcomes in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2016) 0.76
Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. Support Care Cancer (2016) 0.75
Acidic microenvironment and bone pain in cancer-colonized bone. Bonekey Rep (2015) 0.75
Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3. Cancer Res (2017) 0.75
Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors. Patient (2016) 0.75
An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries. Support Care Cancer (2017) 0.75
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol (1993) 18.75
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res (2006) 7.83
Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev (2001) 6.57
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol (2011) 6.16
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes (2003) 5.58
Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol (2008) 4.70
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Defining the clinically important difference in pain outcome measures. Pain (2000) 3.88
Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med (2000) 2.54
General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof (2005) 2.51
Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. Pain (1996) 1.80
Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys (2004) 1.68
Impact of the 7th Edition AJCC staging classification on the NCCN clinical practice guidelines in oncology for gastric and esophageal cancers. J Natl Compr Canc Netw (2013) 1.35
Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer (2005) 1.30
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer (2007) 1.14
Bone metastases: approaches to management. Semin Oncol (2001) 1.08
Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer. Clin Prostate Cancer (2005) 1.05
Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone (2010) 1.04
Pain in castration-resistant prostate cancer with bone metastases: a qualitative study. Health Qual Life Outcomes (2011) 0.96
Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol (2006) 0.95
Biology of bone cancer pain. Clin Cancer Res (2006) 0.94
Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form. J Support Oncol (2011) 0.85
Metastatic bone pain: treatment options with an emphasis on bisphosphonates. Support Care Cancer (2008) 0.84
Expert conference on cancer pain assessment and classification--the need for international consensus: working proposals on international standards. BMJ Support Palliat Care (2011) 0.83
Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. Support Care Cancer (2012) 0.82
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med (2004) 10.41
Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res (2002) 9.99
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29
Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain (2007) 8.89
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet (2012) 6.79
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol (2010) 6.61
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res (2010) 6.09
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res (2006) 4.95
Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain (2004) 4.72
Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst (2005) 4.51
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol (2010) 4.10
Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol (2012) 3.65
Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol (2009) 3.37
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol (2013) 3.23
Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat (2005) 3.23
Family satisfaction with family conferences about end-of-life care in the intensive care unit: increased proportion of family speech is associated with increased satisfaction. Crit Care Med (2004) 3.18
The Rapid Assessment of Physical Activity (RAPA) among older adults. Prev Chronic Dis (2006) 3.12
The use of patient-reported outcomes instruments in registered clinical trials: evidence from ClinicalTrials.gov. Contemp Clin Trials (2009) 2.88
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol (2009) 2.83
Analytical and clinical validation of the 25 OH vitamin D assay for the LIAISON automated analyzer. Clin Biochem (2004) 2.78
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst (2009) 2.77
Estimating clinically significant differences in quality of life outcomes. Qual Life Res (2005) 2.55
Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop. Schizophr Bull (2006) 2.53
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain (2007) 2.47
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res (2011) 2.43
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmun Rev (2010) 2.38
A measure of the quality of dying and death. Initial validation using after-death interviews with family members. J Pain Symptom Manage (2002) 2.33
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol (2007) 2.24
Barriers and facilitators to end-of-life care communication for patients with COPD. Chest (2005) 2.23
Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society's Studies of Cancer Survivors. Cancer (2011) 2.18
Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab (2014) 2.17
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer (2002) 2.17
Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. Neoplasia (2005) 2.17
Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain (2007) 2.07
Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ (2012) 2.04
Mean arterial pressure required for maintaining patency of extracranial-to-intracranial bypass grafts: an investigation with computational hemodynamic models-case series. Neurosurgery (2012) 2.02
Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol (2008) 2.01
Dissatisfaction with medical services among Medicare beneficiaries with disabilities. Arch Phys Med Rehabil (2002) 1.99
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol (2008) 1.98
Symptoms and quality of life in diverse patients undergoing hematopoietic stem cell transplantation. J Pain Symptom Manage (2012) 1.97
Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol (2012) 1.90
Studying communication about end-of-life care during the ICU family conference: development of a framework. J Crit Care (2002) 1.90
Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value Health (2013) 1.87
A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation (2004) 1.87
Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol (2010) 1.85
Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. Pain (2010) 1.84
Evaluation of the methodological quality of systematic reviews of health status measurement instruments. Qual Life Res (2009) 1.82
Premature ejaculation: results from a five-country European observational study. Eur Urol (2007) 1.79
Rasch fit statistics and sample size considerations for polytomous data. BMC Med Res Methodol (2008) 1.77
Association of depression and life-sustaining treatment preferences in patients with COPD. Chest (2005) 1.77
The German version of the Oral Health Impact Profile--translation and psychometric properties. Eur J Oral Sci (2002) 1.76
A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol (2010) 1.72
A structured review of randomized controlled trials of weight loss showed little improvement in health-related quality of life. J Clin Epidemiol (2005) 1.71
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine (2004) 1.70
Patient training in cancer pain management using integrated print and video materials: a multisite randomized controlled trial. Pain (2008) 1.69
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res (2008) 1.67
Authors' reply to Tendas et al. J Pain Symptom Manage (2013) 1.66
A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group. J Palliat Med (2010) 1.64
Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck (2007) 1.63
Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency? Breast Cancer Res Treat (2010) 1.62
A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol (2012) 1.61
Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat (2007) 1.61
Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun (2010) 1.58
The Norwegian brief pain inventory questionnaire: translation and validation in cancer pain patients. J Pain Symptom Manage (2002) 1.58
Quality of dying and death in two medical ICUs: perceptions of family and clinicians. Chest (2005) 1.53
The mathematical relationship among different forms of responsiveness coefficients. Qual Life Res (2007) 1.53
Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol (2006) 1.52
Prevalence of secondary conditions among people with disabilities. Am J Public Health (2004) 1.52
Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 1.52
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol (2010) 1.51
Inter-rater agreement and reliability of the COSMIN (COnsensus-based Standards for the selection of health status Measurement Instruments) checklist. BMC Med Res Methodol (2010) 1.50
Asking the community about cutpoints used to describe mild, moderate, and severe pain. J Pain (2006) 1.48
Osteonecrosis of the jaw and oral health-related quality of life after adjuvant zoledronic acid: an adjuvant zoledronic acid to reduce recurrence trial subprotocol (BIG01/04). J Clin Oncol (2013) 1.48
Adolescent quality of life, part I: conceptual and measurement model. J Adolesc (2002) 1.48
Fatigue and sleep disturbance in patients with cancer, patients with clinical depression, and community-dwelling adults. J Pain Symptom Manage (2003) 1.47
The role of statins in cancer therapy. Oncologist (2006) 1.46
Patient-reported outcomes: instrument development and selection issues. Value Health (2007) 1.46
Cancer pain management among underserved minority outpatients: perceived needs and barriers to optimal control. Cancer (2002) 1.46
Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol (2007) 1.44
Trajectories of health for older adults over time: accounting fully for death. Ann Intern Med (2003) 1.44
Assessing meaningful change in quality of life over time: a users' guide for clinicians. Mayo Clin Proc (2002) 1.43
Diagnosing and treating breast cancer in elderly women: a call for improved understanding. J Am Geriatr Soc (2007) 1.43
Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer (2008) 1.43